The estimated Net Worth of Daniel G Welch is at least $37.5 Million dollars as of 28 August 2023. Mr. Welch owns over 4,925 units of Seagen Inc stock worth over $2,454,524 and over the last 17 years he sold SGEN stock worth over $34,566,441. In addition, he makes $431,036 as Independent Director at Seagen Inc.
Daniel has made over 15 trades of the Seagen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 4,925 units of SGEN stock worth $1,029,719 on 28 August 2023.
The largest trade he's ever made was selling 58,750 units of Seagen Inc stock on 2 November 2020 worth over $9,760,138. On average, Daniel trades about 4,412 units every 70 days since 2007. As of 28 August 2023 he still owns at least 10,725 units of Seagen Inc stock.
You can see the complete history of Mr. Welch stock trades at the bottom of the page.
Daniel G. Welch is Independent Director of Seattle Genetics, Inc., since June 2007. From January 2015 to February 2018, Mr. Welch served as an Executive Partner of Sofinnova Ventures, a venture capital firm. Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a formerly publicly-traded biotechnology company, from September 2003 until InterMune’s acquisition by Roche Holdings in September 2014, and, from May 2007 to October 2014, he served in the additional role of Chairman of the Board of InterMune. Before joining InterMune, he was Chairman and Chief Executive Officer of Triangle Pharmaceuticals from 2002 to 2003, which was acquired by Gilead in 2003. Prior to that, he was President of Biopharmaceuticals at Elan Corporation from 2000 to 2002. During his tenure at Elan he was responsible for its U.S. commercial operations, international subsidiaries, R&D and diagnostics businesses. From 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo, now Sanofi-Aventis, including Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina. In addition to Seattle Genetics, Mr. Welch serves as a director of Intercept Pharmaceuticals, Inc. and Chairman of the Board at Ultragenyx Pharmaceuticals, Inc., both publicly-traded biotechnology companies. Since August 2018, Mr. Welch has served as Executive Chairman of Levo Therapeutics, a private biotechnology firm. Previously, he served as a Director of Hyperion Therapeutics until its acquisition by Horizon Pharma in 2015 and Chairman of the Board of Avexis, Inc. until its acquisition by Novartis Pharmaceuticals in 2018.
As the Independent Director of Seagen Inc, the total compensation of Daniel Welch at Seagen Inc is $431,036. There are 16 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.
Daniel Welch is 62, he's been the Independent Director of Seagen Inc since 2007. There are 4 older and 16 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: